Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26326421 | 0.89 | NPC1 (0.37) | MAPTSMN1; SMN2MAPK1PTGDR2GAA | |
| SCHEMBL24176068 | 0.86 | PTGDR2 (0.32) | MAPTMAPK1PTGDR2HTTLMNA | |
| SCHEMBL24176071 | 0.81 | PIK3CD (0.31) | MAPTPOLBALDH1A1 | |
| SCHEMBL24469132 | 0.81 | NPC1 (0.31) | ALDH1A1 | |
| SCHEMBL24176205 | 0.80 | NPC1 (0.32) | — | |
| SCHEMBL26326300 | 0.78 | MAPT (0.43) | MAPTSMN1; SMN2MAPK1GAAKDM4E | |
| SCHEMBL24469138 | 0.76 | GLP1R (0.31) | — | |
| SCHEMBL24176212 | 0.75 | PARP1 (0.35) | — | |
| SCHEMBL24166219 | 0.74 | NPC1 (0.41) | MAPTMAPK1HTTLMNA | |
| SCHEMBL30586613 | 0.74 | NPC1 (0.41) | MAPTMAPK1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220002299-A1 | TRICYCLIC PYRIDONE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2022-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002299-A1 | TRICYCLIC PYRIDONE COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | MAPT 4580/4885SMN1; SMN2 4294/4885MAPK1 486/4885 |
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | MAPT 4580/4885SMN1; SMN2 4294/4885MAPK1 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.